Want to see HK:6078 full AI Analyst Report?
6078 Stock Chart & Stats
HK$9.93
HK$0.07(0.70%)
At close: 4:00 PM EDT
HK$9.93
HK$0.07(0.70%)
Day’s Range― - ―
52-Week RangeHK$8.10 - HK$17.72
Previous CloseN/A
Volume725.80K
Average Volume (3M)7.15M
Market Cap
HK$6.12B
Enterprise ValueHK$9.60K
Total Cash (Recent Filing)HK$741.02M
Total Debt (Recent Filing)HK$2.45B
Price to Earnings (P/E)122.4
Beta1.46
Next Earnings
Aug 27, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding618,499,000
10 Day Avg. Volume3,556,037
30 Day Avg. Volume7,151,771
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)1.02
Price to Sales (P/S)1.72
P/FCF Ratio14.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.35Price Target Upside64.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.84
Revenue Forecast (FY)HK$4.28B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthSustained top-line expansion over multiple years indicates the group's ability to grow patient volumes and scale hospital operations. Durable revenue growth supports investment in facilities and services, improving long-term market position and enabling operating leverage if cost control stabilizes.
Manageable Leverage And Growing Equity BaseRelatively low debt levels versus equity provide financial flexibility for capex, expansions and shocks to reimbursement. An improving leverage profile with expanding assets and equity underpins the group's capacity to fund growth internally and limits refinancing risk over the medium term.
Improving Operating Cash And FCF ReboundA rebound in free cash flow and steady positive operating cash flow signal improving cash generation that supports reinvestment, deleveraging or strategic M&A. While conversion is mixed historically, the 2025 improvement indicates the business can generate CEO-level capital over time when trends hold.
Bears Say
Sharp Profitability Drop In 2025A large drop in net margin and operating margins materially reduces return on equity and internal funds for reinvestment. If driven by structural cost pressures or reimbursement shifts, this deterioration can persist and impair long-term earnings quality and ability to fund growth without external capital.
Recent Revenue Decline / VolatilityA negative revenue reading signals recent softness after prior growth, implying variability in patient volumes, pricing or payor mix. Revenue volatility undermines planning for capacity and margins, and long-term recovery depends on sustained demand or improved case mix rather than one-off rebounds.
Inconsistent Cash ConversionWeak and inconsistent cash conversion means reported profits do not fully translate to spendable cash, constraining capex, working capital and strategic moves. Persistent variability in working capital or one-off items reduces financial resilience and increases reliance on external funding in stress periods.
Hygeia Healthcare Holdings Co., Ltd. News
6078 FAQ
What was Hygeia Healthcare Holdings Co., Ltd.’s price range in the past 12 months?
Hygeia Healthcare Holdings Co., Ltd. lowest stock price was HK$8.10 and its highest was HK$17.72 in the past 12 months.
What is Hygeia Healthcare Holdings Co., Ltd.’s market cap?
Hygeia Healthcare Holdings Co., Ltd.’s market cap is HK$6.12B.
When is Hygeia Healthcare Holdings Co., Ltd.’s upcoming earnings report date?
Hygeia Healthcare Holdings Co., Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.
How were Hygeia Healthcare Holdings Co., Ltd.’s earnings last quarter?
Hygeia Healthcare Holdings Co., Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.151 earnings per share for the quarter, missing the consensus estimate of -HK$0.139 by -HK$0.012.
Is Hygeia Healthcare Holdings Co., Ltd. overvalued?
According to Wall Street analysts Hygeia Healthcare Holdings Co., Ltd.’s price is currently Undervalued.
Does Hygeia Healthcare Holdings Co., Ltd. pay dividends?
Hygeia Healthcare Holdings Co., Ltd. pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of N/A. See more information on Hygeia Healthcare Holdings Co., Ltd. dividends here
What is Hygeia Healthcare Holdings Co., Ltd.’s EPS estimate?
Hygeia Healthcare Holdings Co., Ltd.’s EPS estimate is 0.35.
How many shares outstanding does Hygeia Healthcare Holdings Co., Ltd. have?
Hygeia Healthcare Holdings Co., Ltd. has 618,499,000 shares outstanding.
What happened to Hygeia Healthcare Holdings Co., Ltd.’s price movement after its last earnings report?
Hygeia Healthcare Holdings Co., Ltd. reported an EPS of -HK$0.151 in its last earnings report, missing expectations of -HK$0.139. Following the earnings report the stock price went down -0.348%.
Which hedge fund is a major shareholder of Hygeia Healthcare Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in HK:6078
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hygeia Healthcare Holdings Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.60%
Trailing 12-Months
Company Description
Hygeia Healthcare Holdings Co., Ltd.
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
6078 Stock 12 Month Forecast
Average Price Target
HK$16.35
▲(64.65% Upside)
Technical Analysis
Aidigong Maternal & Child Health
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―